» Articles » PMID: 24693477

The Expressions of Stem Cell Markers: Oct4, Nanog, Sox2, Nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in Bladder, Colon, and Prostate Cancer, and Certain Cancer Cell Lines

Overview
Journal Anat Cell Biol
Date 2014 Apr 3
PMID 24693477
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Uncontrolled self-renewal plays a direct function in the progression of different types of carcinomas. The same molecular pathway that manages self-renewal in normal stem cells also seems to manage cancer stem cells. Here, we examine the expressions of self-renewal regulatory factors Oct4, Nanog, Sox2, nucleostemin, Zfx, Esrrb, Tcl1, Tbx3, and Dppa4 in tissue samples of colon, prostate, and bladder carcinomas as well as cancer cell lines HT-29, Caco-2, HT-1376, LNCaP, and HepG2. We used reverse transcriptase polymerase chain reaction to examine expressions of the above mentioned regulatory factors in cancer cell lines HT-29, Caco-2, HT-1376, LNCaP, and HepG2 and in 20 tumor tissue samples. Total RNA was isolated by the ISOGEN method. RNA integrity was checked by agarose gel electrophoresis and spectrophotometry. Expressions of Oct4 and nucleostemin at the protein level were determined by immunocytochemistry. A significant relationship was found between tumor grade and self-renewal gene expression. Expressions of stem cell specific marker genes were detected in all examined cancer cell lines, in 40% to 100% of bladder cancer samples, and in 60% to 100% of colon and prostate cancer samples. Oct4 expressed in 100% of tumor tissue samples. Our data show that stem cell markers Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Esrrb, Tcl1, Tbx3, and Dppa4 significantly express in cancer cell lines and cancer tissues. Hence, these markers might be useful as potential tumor markers in the diagnosis and/or prognosis of tumors.

Citing Articles

HIV-1 Tat-induced disruption of epithelial junctions and epithelial-mesenchymal transition of oral and genital epithelial cells lead to increased invasiveness of neoplastic cells and the spread of herpes simplex virus and cytomegalovirus.

Tugizov S Front Immunol. 2025; 16:1541532.

PMID: 40018040 PMC: 11866325. DOI: 10.3389/fimmu.2025.1541532.


The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.

Griffin R, Shuman L, Yamashita H, Wu Q, Chen G, Brown R Am J Clin Exp Urol. 2024; 12(2):88-99.

PMID: 38736621 PMC: 11087210. DOI: 10.62347/MEQO6014.


Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights.

Soleimani A, Saeedi N, Al-Asady A, Nazari E, Hanaie R, Khazaei M Curr Pharm Des. 2024; 30(18):1386-1397.

PMID: 38623972 DOI: 10.2174/0113816128291321240329050945.


KPT6566 induces apoptotic cell death and suppresses the tumorigenicity of testicular germ cell tumors.

Sun R, Lee E, Lee S, Kim G, Kim J Front Cell Dev Biol. 2023; 11:1220179.

PMID: 38020885 PMC: 10652286. DOI: 10.3389/fcell.2023.1220179.


Circular RNA ZNF800 (hsa_circ_0082096) regulates cancer stem cell properties and tumor growth in colorectal cancer.

Rengganaten V, Huang C, Wang M, Chien Y, Tsai P, Lan Y BMC Cancer. 2023; 23(1):1088.

PMID: 37950151 PMC: 10636831. DOI: 10.1186/s12885-023-11571-1.


References
1.
Matthai C, Horvat R, Noe M, Nagele F, Radjabi A, van Trotsenburg M . Oct-4 expression in human endometrium. Mol Hum Reprod. 2006; 12(1):7-10. DOI: 10.1093/molehr/gah254. View

2.
Fan Y, Liu Z, Zhao S, Lou F, Nilsson S, Ekman P . Nucleostemin mRNA is expressed in both normal and malignant renal tissues. Br J Cancer. 2006; 94(11):1658-62. PMC: 2361296. DOI: 10.1038/sj.bjc.6603145. View

3.
Lock R . TCL1: a new drug target in lymphoid and germ-cell malignancies?. Int J Biochem Cell Biol. 2003; 35(12):1614-8. DOI: 10.1016/s1357-2725(03)00146-8. View

4.
Cellot S, Sauvageau G . Zfx: at the crossroads of survival and self-renewal. Cell. 2007; 129(2):239-41. DOI: 10.1016/j.cell.2007.04.002. View

5.
Renard C, Labalette C, Armengol C, Cougot D, Wei Y, Cairo S . Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res. 2007; 67(3):901-10. DOI: 10.1158/0008-5472.CAN-06-2344. View